Skip to content
Companies

NextSense

EEG earbuds that track brainwaves to deepen sleep

Raised to date

$16.3M

of $19.3M offered across 1 Form D filing

Still open
$3M
Investors
29
Last filed
Nov 12, 2025

About

NextSense is a Mountain View, California neurotech company that builds wireless earbuds with built-in EEG sensors to measure brain activity outside of a sleep lab. Spun out of Alphabet's X moonshot factory, where it began as an in-ear EEG investigation into human-computer interaction, the company now sells consumer Smartbuds that read brainwaves and play precisely timed audio to deepen sleep and support daytime focus. It also operates a neural data and software platform used for brain-health research, disease monitoring such as seizure detection, and drug development. NextSense raised a $16 million Series A announced in November 2025 and began shipping Smartbuds commercially in February 2026.

Rather than passively tracking sleep like a wrist wearable, the earbuds read clinical-grade EEG from inside the ear in real time and close the loop with timed audio stimulation that actively alters sleep depth.

Funding

  • EquityFiled Nov 12, 2025Form D/A
    $16.3M/ $19.3M

Product

NextSense Smartbuds

Consumer neurotech wearable

Truly wireless earbuds with clinical-grade dry-contact EEG electrodes that read brainwaves in real time and respond with timed audio. In Sleep mode they deliver gentle pink-noise pulses phase-locked to slow-wave activity to deepen restorative sleep; in Focus mode they adapt daytime audio across open-ended, Pomodoro, and alertness-aligned sessions. The companion iOS app handles sleep staging, brainwave analysis, and focus tracking with no subscription required.

  • Six clinical-grade dry-contact EEG electrodes with a specialized coating
  • 2-channel 24-bit EEG sampled at 1000 Hz
  • Closed-loop pink-noise audio pulses timed to slow-wave sleep

Built for

Consumers who want to improve sleep quality and daytime focus and are willing to wear a sensing earbud overnight, plus researchers and drug developers who need real-world brain data outside a clinical lab.

People on file